(Q43032126)

12 November 2017

title

Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. (English)

1 reference

12 November 2017

4

1 reference

12 November 2017

Bonaventura Clotet Sala

series ordinal

3

object named as

Bonaventura Clotet

1 reference

12 November 2017

2

Cristina Tural

1 reference

12 November 2017

Sandra Franco

1

1 reference

12 November 2017

publication date

4 October 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

123

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

161-169

1 reference

Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Phylogenies from molecular sequences: inference and reliability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

The Los Alamos hepatitis C sequence database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Genetic screen for monitoring hepatitis C virus NS3 serine protease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Clinical Evaluation of Two Methods for Genotyping Hepatitis C Virus Based on Analysis of the 5' Noncoding Region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Genetic diversity and evolution of hepatitis C virus--15 years on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.09.001

10.1016/J.VIRUSRES.2006.09.001

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference